Lung cancer drug: AstraZeneca India wins CDSCO nod for Durvalumab for specified additional indication
Written By : Ruchika Sharma
Medically Reviewed By : Dr. Kamal Kant Kohli
Published On 2024-09-24 06:30 GMT | Update On 2024-09-24 06:30 GMT
Bengaluru: AstraZeneca Pharma India Limited has received permission to import for sale and distribution of Durvalumab 120 mg/2.4 mL and 500 mg/10 mL solution for infusion from the Central Drugs Standard Control Organisation (CDSCO), Directorate General of Health Services, Government of India for an additional indication, subject to the receipt of related statutory approvals, if any.
“Durvalumab in combination with chemotherapy as neoadjuvant treatment, followed by Durvalumab as monotherapy after surgery, is indicated for the treatment of patients with resectable (tumours 4 cm and/or node positive) non-small cell lung cancer (NSCLC) and no known epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) rearrangements”.
According to GLOBOCAN 2022 data, lung cancer remains the fourth most common cause of cancer-related mortality in India. Around 15% of patients with NSCLC in India have resectable disease representing a significant patient population.
Dr Anil Kukreja, Vice-President, Medical Affairs and Regulatory, AstraZeneca Pharma India Ltd, said, “We are following the science to understand cancer and all its complexities to discover, develop and deliver life-changing treatments to transform survival. This approval reflects our focus on constantly exploring new novel treatment combinations, to deliver to those patients where we can make huge impact. The AEGEAN trial shows this novel Imfinzi-based regimen meaningfully improved outcomes in resectable lung cancer, further validating the importance of moving lung cancer diagnosis and treatment to earlier stages of disease where patients have the highest potential for cure.”.
Dr Sanjeev Panchal, Managing Director & Country President, AstraZeneca Pharma India Ltd, “Patients are at the centre of everything we do. We are constantly pushing the boundaries of science, to provide precision medicines to the patients who can benefit most from them. We are focused on bringing innovative medicines faster to India for patients and remain committed to bringing novel treatment approaches like AEGEAN to early lung cancer settings”.
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in four therapy areas - Oncology, Cardiovascular, Renal & Metabolism and Respiratory and Rare Diseases. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Established in 1979, it is headquartered at Bengaluru, Karnataka in India.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.